GeneReach Biotechnology (4171) — Cash Flow Reinvestment Rate
GeneReach Biotechnology (4171) has a Cash Flow Reinvestment Rate of 5.12x as of June 2026, reinvesting NT$32.19 Million (capex NT$8.13 Million plus investments NT$24.06 Million) from operating cash flow of NT$6.28 Million. See GeneReach Biotechnology (4171) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
GeneReach Biotechnology Cash Flow Reinvestment Rate (2018–2022)
Historical reinvestment intensity for GeneReach Biotechnology across 4 annual periods. For the full cash flow conversion analysis, see 4171 operating cash flow.
Annual Cash Flow Reinvestment Rate for GeneReach Biotechnology (2018–2022)
Year-by-year capital reinvestment analysis for GeneReach Biotechnology. See how financially flexible is GeneReach Biotechnology to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.26x | NT$92.92 Million | NT$357.63 Million | NT$44.90 Million | ▲ +361.7% |
| 2021 | 0.06x | NT$19.64 Million | NT$348.99 Million | NT$15.79 Million | ▼ -86.1% |
| 2020 | 0.40x | NT$68.72 Million | NT$169.82 Million | NT$64.87 Million | ▼ -62.3% |
| 2018 | 1.07x | NT$6.16 Million | NT$5.74 Million | NT$2.31 Million | — |